Cosmo Bio Company,Limited
Stock Price Chart
2026/08/05 UpdatedPrice Trend
2026/08/05 UpdatedPrice & Trading Details
2026/08/05 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/02| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥25 | -50.0% |
| 2025 | ¥50 | 0.0% |
| 2024 | ¥50 | +66.7% |
| 2023 | ¥30 | -16.7% |
| 2022 | ¥36 | - |
Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥9,553M | ¥9,340M | ¥10,037M | ¥10,766M |
| Gross Profit | ¥3,440M | ¥3,249M | ¥3,329M | ¥3,702M |
| Operating Income | ¥816M | ¥520M | ¥319M | ¥343M |
| Pretax Income | ¥790M | ¥653M | ¥369M | ¥504M |
| Net Income | ¥517M | ¥442M | ¥262M | ¥337M |
| EPS | ¥89.13 | ¥75.97 | ¥45.05 | - |
| Operating Margin | 8.54% | 5.57% | 3.18% | 3.19% |
| Balance Sheet | ||||
| Total Assets | ¥10,313M | ¥10,872M | ¥11,723M | ¥12,662M |
| Total Equity | ¥8,052M | ¥8,444M | ¥8,966M | ¥9,373M |
| Total Liabilities | ¥2,261M | ¥2,428M | ¥2,757M | ¥3,289M |
| Cash | ¥3,036M | ¥2,826M | ¥2,393M | ¥2,747M |
| Interest-bearing Debt | ¥20M | ¥20M | ¥20M | ¥20M |
| Equity Ratio | 78.08% | 77.67% | 76.48% | 74.02% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥284M | ¥736M | ¥241M | ¥595M |
| Investing CF | -¥291M | -¥758M | -¥217M | ¥43M |
| Financing CF | -¥236M | -¥201M | -¥479M | -¥283M |
| Free CF | ¥180M | ¥636M | -¥35M | ¥314M |
| Efficiency | ||||
| ROE | 6.42% | 5.23% | 2.92% | 3.60% |
| ROA | 5.01% | 4.07% | 2.23% | 2.66% |
Latest IR Information
-
FY2026 December Quarter 2 Interim Consolidated Financial Results [Japanese GAAP] (Consolidated)
The interim consolidated results for the six months ended December 2026 show net sales of 5,914 million yen (YoY +9.5%), operating income of 279 million yen ( +1.2%), ordinary income of 340 million yen (△0.8%), and net income attributable to...
Read more -
Cosmo Bio Earnings Guidance Revision | July 2026
Cosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (up 0.9% vs. previous forecast) and net income attributable to shareholders of 320 million yen (up 45.5% vs....
Read more
Latest News (5 items)
Company Information
About
Cosmo Bio Company,Limited, together with its subsidiaries, operates as a life science trading company worldwide. It is involved in the import, export, manufacture, marketing, sales, and customer support of life science research bio tools, such as reagents, kits, instruments, and software. The company also distributes antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, and bacteria, as well as detection reagents, cell and tissue culture systems, and gene analysis systems; and research instruments, including electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. In addition, it provides drug discovery and custom research services; clinical diagnostics; cell and DNA, and protein engineering solutions; disposable items and general labware; and bioactive substances; consigned services, such as intestinal flora analysis, tear fluid analysis, and cell assays services; and custom peptide synthesis and antibody production services. Further, the company manufactures and sells cell/cell culture products comprising adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem cells, feeder cells, tumor cell lines, macrophage-related, and coating reagents; measurement and staining kits, detection/purification kits related to neurodementia, macrophage/immune, exosome, and anti-saccharification/anti-aging; and biotechnology research equipment, such as constant-temperature transport containers, aluminum block mat heat insulation devices, and dew condensation prevention glass plate. It serves universities, public research institutes, and companies engaged in biological science. Cosmo Bio Company, Limited was founded in 1978 and is headquartered in Koto, Japan.